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ABSTRACT
Acute promyelocytic leukemia (APL) is a
molecularly well-defined disease, characterized
by a specific chromosomal translocation; the
improvement in biologic and clinical
knowledge and subsequent introduction of
molecularly targeted therapies have
transformed the management of APL, with
survival rates now exceeding 80%. Minimal
residual disease (MRD) assessment in APL is
the most important tool for its treatment; the
prognostic role of the molecular detection of
promyelocytic leukemia retinoic acid receptor a
(PML-RARa) transcript after consolidation
therapy in the early identification of the
following hematologic relapse is now well
established and guides preemptive therapy.
First experiences performed with a qualitative
polymerase chain reaction (PCR) approach were
replaced with more accurate real-time
quantitative PCR (RQ-PCR), which guarantees
a numeric quantification of MRD. The
identification of arsenic trioxide (ATO) as a
valid therapy not only in relapsed patients but
also as an alternative to standard therapy alone
or in association with all-trans-retinoic acid
enlarges the setting of validation of MRD
evaluation in APL patients, considering a
possible different clearance of PML-RARa with
innovative therapy different from the standard
ones. MRD monitoring demonstrated its
validity also in the setting of relapsed patients
with interesting results in the autologous and
allogeneic stem cell transplantation setting or
with the use of other biological agents. The aim
of this review is to report and discuss the actual
state of the art of MRD in APL.
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INTRODUCTION
Acute promyelocytic leukemia (APL) is a
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by the presence of a specific chromosomal
translocation—t(15;17) (q22;q21), which leads
to the aberrant expression of the promyelocytic
leukemia retinoic acid receptor a (PML-RARa)
fusion gene (Fig. 1) [1]. In about 2% of cases,
other aberrant translocations, such as
t(11;17)(q23;q21), t(11;17)(q13;q21) and
t(5;17)(q35;q21), and from an interstitial
deletion event on chromosome 17 can involve
fusions between retinoic acid receptor a (RARa)
and other partner genes, such as the
promyelocytic leukemia zinc finger (PLZF),
nuclear mitotic apparatus protein (NuMA),
nucleophosmin, and signal transducer and
activator of transcription 5b (STAT5b) [2–6]. The
aberrant expression of PML-RARa led to the
exaltations of oncogenic signaling and
consequently to the neoplastic transformation
of myeloid cells [7].
An exquisite sensitivity to anthracyclines by
APL blasts was shown for the first time by Jean
Bernard in 1973, but those first encouraging
results in APL treatment were impaired by the
persistent and so far unresolved problem of early
deaths and absence of valid alternative
therapeutic strategies in case of relapse or
refractory disease [8]. The evidence that
all-trans-retinoic acid (ATRA) is highly effective
in the induction of blast differentiation and its
subsequent use in clinical practice induced a
dramatic improvement in the outcome of APL,
especially when associated with standard
chemotherapy [9–11]. Further studies have
widened the molecular knowledge around APL
pathogenesis and have also demonstrated that
arsenic trioxide (ATO) exhibits a significant
antileukemic effect in relapsed and low-/
intermediate-risk newly diagnosed patients [12,
13, 15]. It is of paramount importance that the
baseline correctly identifies the fusion partner
gene, as it is crucial to define the eventual
sensitivity to molecularly targeted therapy: in
fact, it has been demonstrated that
morphological cases such as APL associated
with PLZF and STAT5b are resistant to ATRA,
while ATO activity is restricted only in cases of
PML-RARa alteration [2, 14].
Recently, a cooperative German-Italian
randomized trial demonstrated that the
chemotherapy-free approach with ATRA plus
ATO is superior to the association of ATRA plus
standard chemotherapy in low-intermediate-risk
APL [15]. New therapeutic strategies and
refinement of molecular standardization have
Fig. 1 Schematic representation of the PML/RARalpha hybrid with distinct isoforms. PML promyelocytic leukemia,
RARa retinoic acid receptor a
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transformed APL from an aggressive fatal
disease into one of the most curable
neoplasms; indeed, a low percentage of
patients (10–15%) failed to obtain a durable
remission, and few patients were refractory to
initial therapy [16]. To prevent morphologic
relapse, potentially fatal because it is associated
with concomitant coagulopathy, minimal
residual disease (MRD) monitoring has been
successfully standardized for the early
identification of relapse [17].
Molecular methodologies have deeply
changed the diagnostic and therapeutic
approach to acute leukemias; during the last 3
decades diagnosis and follow-up criteria have
evolved from simple morphologic evaluation to
highly sensitive molecular methods. The
standard reverse transcriptase polymerase
chain reaction (RT-PCR) represents an
important methodology for diagnosis
assessment, but it was demonstrated to be less
suitable for MRD monitoring during follow-up,
because it was only informative about the
disease status (positive or negative) and
provided no real quantification of MRD.
The introduction of real-time quantitative
PCR (RQ-PCR) overcame the limits of previous
methodologies with sensitive and accurate
quantification of gene expression. Parallel
amplification of the target gene and one or
more control genes represented a crucial
innovation. The amplification of a control
gene, mostly represented by the Abelson gene,
avoided false-negative results related to
suboptimal amplification of PCR results [18].
The aim of this review is to highlight the
principal indications and new insights in MRD
monitoring in APL and to overview the rationale
of MRD-based preemptive therapy. This article is
based on previously conducted studies and does
not involve any new studies of human or animal





A specific molecular hallmark in APL and the
possibility to monitor the MRD with accurate
and standardized RT-PCR allow strict molecular
monitoring during the frontline treatment and
follow-up phase.
Cooperative groups in Italy [Gruppo Italiano
Malattie EMatologiche dell’Adulto (GIMEMA)]
and Spain [Programa para el Tratamiento de
Hemopatias Malignas (PETHEMA)] have largely
contributed to the correct definition of the
standard of care in APL. In 1997, the GIMEMA
group introduced a combination of ATRA and
anthracycline as first-line induction therapy
(AIDA trial), followed by three cycles of
standard chemotherapy consolidation; after
the third consolidation, a qualitative
evaluation of MRD showed the absence of the
PML/RARa transcript in 98% of patients. This
protocol guaranteed event-free survival (EFS)
rates of 83% at 1 year and 79% at 2 years [19].
The PETHEMA group introduced a similar trial
slightly different from AIDA by the absence of
cytarabine and etoposide in consolidation.
RT-PCR MRD evaluation was performed at the
end of induction treatment and consolidation,
with a complete molecular remission rate of
51% and 93%, respectively. In this trial similar
overall survival (OS) (82%) and EFS (79%)
compared to the AIDA protocol were reported:
the authors concluded that cytarabine and
etoposide have a minor role in the treatment
of newly diagnosed APL [20].
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Fenaux et al. investigated the role of
maintenance therapy in APL patients [9].
Patients in complete remission (CR) were
randomized to receive 2-year maintenance
therapy with continuous low-dose
chemotherapy (6-mercaptopurine,
methotrexate), intermittent ATRA (15 days every
3 months), a combination of both agents or no
maintenance therapy. The authors concluded
that a maintenance therapy combining
chemotherapy and intermittent ATRA reduced
the incidence of relapse in APL patients [9].
Although the association of ATRA and
anthracyclines guaranteed high response rates,
a minority of patients did not reach CR or early
relapse. A predictive model was introduced to
identify risk of relapse earlier. Three risk
categories were proposed considering the
clinical characteristics at diagnosis [high risk:
white blood cell count (WBC) C 10 9 109/l;
intermediate risk: WBC B 10 9 109/l and
platelet count B 40 9 109/l; low risk:
WBC B 10 9 109/l and platelet
count C 40 9 109/l] [21], and consolidation
therapy was adapted to reduce the toxicity and
rate of mortality in CR. It should be mentioned
that, at the present time, the prognostic
relevance based on platelet levels and the
WBC assumes a minor role and is not yet
considered strictly prognostic with the possible
exception of the WBC. At the same time, a
specific correlation between MRD positivity and
the subsequent risk of clinical relapse has been
reported [17, 22–27]; in particular, it has
become clear that the assessment at the end of
consolidation is the more appropriate point for
performing MRD evaluation compared to the
end of induction. Otherwise, molecular
characterization of morphologic-resembling
APL with an atypical transcript clarifies the
correlation between the molecular pattern and
clinical resistance to treatment [2–6].
Considering the prognostic value of
molecular monitoring for the early
identification of relapse, in 1999 the GIMEMA
group showed for the first time that molecularly
guided preemptive therapy confers an
advantage compared to patients treated at the
time of hematological overt relapse; they
reported cumulative 2-year progression-free
survival (PFS) of 85% in patients preemptively
treated based on molecular relapse, which was
statistically significant when compared with the
results from previous series in which treatment
was initiated in the presence of hematological
relapse (2-year PFS: 44%). Molecular relapse was
considered as the reappearance of a positive
RT-PCR (sensitivity 10-4) in two consecutive
tests performed on bone marrow (BM). The
small number of patients and absence of
quantitative evaluation of PML-RARa did not
allow stratification of the risk of relapse [28]. In
2007, the PETHEMA group also confirmed that
salvage therapy in the presence of molecular
relapse guaranteed a better outcome compared
to treatment at the time of hematological
relapse [29] (Table 1). Also in this study MRD
was assessed with qualitative RT-PCR; it is
remarkable that the RT-PCR methods used in
those studies showed an inferior sensitivity
(10-4) of almost two logs compared to other
techniques used for other types of leukemia in
the same period. This difference is largely
attributable to the intrinsically lower
sensitivity of RT-PCR for the PML/RARa
transcript in respect to other AML genes, such
as BRC-ABL [30] or AML/ETO [31]. This inferior
sensitivity can explain the high probability of
subsequent hematological relapse
demonstrated in different experiences [27, 32].
Conversely, when more sensitive MRD
detection for PML-RARa methods is used
(10-6), a clear correlation between molecular
and hematological relapse became less clear.
122 Rare Cancers Ther (2015) 3:119–132
Tobal et al. showed that some APL patients in
long-term remission may show RT-PCR MRD
positivity without ever experiencing a further
hematological relapse [33].
In order to overcome limitation bias related
to qualitative PCR, standardized quantification
of the PML/RARa copy number based on
RQ-PCR has become the new alternative for
MRD monitoring. Also with RQ-PCR,
Santamaria et al. confirmed the correlation
between high levels of normalized copy
numbers of the PML-RARa transcript and risk
of relapse when it was evaluated at the end of
consolidation (high risk of relapse when the
normalized copy number is[10, persistence in
hematological remission when the value is\1)
[34]. These data confirmed that the prognostic
relevance of MRD became effective when it was
identified after consolidation therapy, and it is
concordant with what was demonstrated in
previous experiences [17, 32, 35]. RQ-PCR
offers several advantages compared to the
qualitative method: Flora et al. [36]
demonstrated that RQ-PCR enhanced
sensitivity and reduced the risk of sample
contamination. Moreover, it allowed
performing quality control of the process by
the quantification of an independent control
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Lo-Coco et al. [28] 14/253 (5%) 14 patients with positive
MRD selected from
AIDA trials
– CR: 12/14 (85%)
Esteve et al. [29] 16/549 (3%) 16 patients with positive
MRD selected from
LPA96 and LPA99 trials
– CR: 14/16 (87%)
APL acute promyelocytic leukemia, CR complete remission, mCR molecular complete remission, MRD minimal residual
disease
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gene amplification (ABL gene), avoiding
obtaining a false negativity related to a
suboptimal amplification of the PCR result.
Finally, the quantification of the gene
transcript allowed evaluating the increase of
the MRD over time, which is essential for
making the correct treatment decision [37, 38].
The validation of the novel RQ-PCR
approach came from a large UK study that
analyzed samples from 406 patients receiving
ATRA and anthracycline-based therapy, most of
them enrolled in the AML 15 trial [39]. A total
of 6727 BM and peripheral blood (PB) samples
were analyzed. With the higher sensitivity of
RQ-PCR, 95% of patients achieved complete
molecular remission at the end of
consolidation; patients with a positive RQ-PCR
were preemptively treated with ATO.
Quantitative MRD assessment in BM was
shown to be the most powerful predictor of
relapse-free survival (RFS) in multivariable
analysis [hazard ratio 17.87; 95% confidence
interval (CI) 6.88–46.41], superior to the
presenting WBC (hazard ratio 1.02; 95% CI
1.00–1.03). Also in this article the evaluation of
MRD in PB was not significant because of the
lack of sensitivity, which limits the opportunity
to use PB for monitoring [40].
Regarding the management of high-risk
patients, a risk-tailored treatment has been
established; high-risk patients benefit from a
more intensive consolidation therapy. Data
from two PETHEMA trials (LPA96 and LPA99)
showed that an increased dose of anthracyclines
enhanced the antileukemic efficacy [41].
Although risk stratification was performed
using clinical parameters, it is of interest that
six out of seven MRD-positive patients were
high risk, and a linear correlation between
clinical and molecular parameters has been
shown [43]. The GIMEMA trial AIDA-2000
confirmed the validity of a risk-tailored
therapy and demonstrated that the
introduction of cytarabine in consolidation




WITH ATO IN FRONTLINE THERAPY
The efficacy of ATO in relapsed/refractory APL is
well defined; during the last years, the
possibility of its use in the first-line therapy
was assessed, and this new approach opens a
new scenario in the molecular monitoring of
APL. It has been demonstrated that molecular
clearance of APL blast cells using ATO as
induction therapy is different compared to
ATRA alone or ATRA plus chemotherapy
regimens [43].
The variability in PML-RARa clearance
between ATRA and ATO is probably influenced
by the different mechanism of action of the two
drugs on APL blast: while ATRA barely promotes
blast differentiation, ATO at high concentration
(1–2 9 10-6 M) induces apoptosis, mainly by
activating the mitochondria-mediated intrinsic
apoptotic pathway. Indeed, ATO at low
concentrations (0.25–0.5 9 10-6 M) and with a
longer treatment course promotes the
differentiation of APL cells [44].
For this reason, data regarding MRD
assessment derived from conventional
treatment protocols may not be applicable in
this particular setting.
First evidence of ATO efficacy in newly
diagnosed patients came from developing
countries where standard regimens are
associated with significant economic costs that
make them unaffordable. In 2006, an Iranian
group published their experience with 111
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patients with both newly diagnosed and
relapsed APL patients who received ATO in
monotherapy. Induction was performed with
ATO at 0.15 mg/kg/day until hematological
remission, followed by consolidation with the
same schedule for 28 total infusions. The
authors reported a 1- and 2-year disease-free
survival (DFS) of 88.3% and 63.7%, respectively;
in patients with relapsed disease, 19/24 (79%)
obtained a second remission. MRD monitoring
was performed with a semi-sensitive reverse
transcription method on PB after the
consolidation phase and 12 months after CR
[45]. Long-term results after 5 years of this trial
reported a morphologic CR rate of 85.8%, while
DFS was 64.4 ± 4%. MRD was performed with
the same method utilized in the first trial [44].
The Indian group produced a similar trial in
which induction, consolidation and
maintenance were performed with ATO as a
single agent: in 2006 they reported an interim
analysis in which hematologic CR was achieved
in 86.1% of patients. At a median follow-up of
25 months, the 3-year EFS, DFS and OS were
74.87%, 87.21% and 86.11%, respectively. Side
effects were mild and reversible [47]. The
long-term follow-up showed that the 5-year
EFS, DFS and OS were 69%, 80% and 74.2%,
respectively [48], and confirmed the safety
profile of ATO. Chendamarai et al. published
on the specific role of MRD monitoring in
ATO-treated patients as frontline therapy: the
evaluation was performed using a quantitative
RT-PCR on the PB sample [49]. They showed in
multivariate analysis that a positive RQ-PCR at
the end of the induction was associated with an
increased risk of relapse. RQ-PCR negativity in
low-risk patients (WBC B 5 9 109/l; platelet
count C 20 9 109/l) was predictive of
subsequent relapse. After the achievement of
molecular remission, the MRD monitoring
strategy predicted relapse in 60% of cases, with
an overall sensitivity and specificity of 60% and
93.2%, respectively. Therefore, high-risk
patients and those with RQ-PCR positivity
after induction benefit from serial RQ-PCR
monitoring for 3 years after completion of
therapy [49]. Considering these results, it can
be assumed that although ATO is efficacious in
inducing morphological RC, the probability of
relapse seems to be higher in this group in
comparison with other standard approaches.
Regarding ATO’s role in consolidation for
APL-naı¨ve patients, Powell et al. investigated
its role in a randomized trial: after a standard
induction with ATRA, daunorubicin and
cytarabine, patients were randomly assigned to
receive consolidation therapy with two courses
of ATRA and daunorubicin or two courses of
ATO. They reported a better 3-year EFS and DFS
in the ATO group in comparison with standard
consolidation (80% vs. 63% and 90% vs. 70%,
respectively) [50].
Recently ATO was successfully tested in
first-line therapy as an alternative to the
standard chemotherapy approach; first
experiences using ATRA in association with
ATO in untreated patients were reported by
Estey et al. [51] and recently updated by
Ravandi et al. [52], suggesting the potential
efficacy and good safety profile of this
association.
All this evidence demonstrated that ATO is
effective also in first-line therapy, either as
induction or consolidation therapy, and not
only in the setting of relapsed patients. Lo-Coco
et al. demonstrated that frontline therapy with
ATRA and ATO for low-/intermediate-risk
patients might be superior to the standard
association of ATRA plus chemotherapy, with
a better safety profile. In this experience the
authors also investigated whether ATO can
induce a different pattern of clearance of the
molecular burden; MRD evaluation with
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RT-PCR was also performed after the induction
phase in addition to conventional
measurement at the end of the third
consolidation, but no statistical differences
were noted between the ATO and standard
group [15]. The identification of this novel
targeted therapy raises new questions about
the correct management of APL: the ATRA-ATO
association in frontline therapy seems to be
effective, but for high-risk patients, according to
Sanz [21], the use of a chemotherapeutic
approach probably cannot be abandoned tout
court. Future experiences may better clarify the
role of ATO in first-line therapy for high-risk
patients.
MRD MONITORING IN RELAPSED
PATIENTS
The rationale of molecular monitoring in APL
patients is to detect disease relapse early and
consequently to provide a preemptive
intervention; the preemptive approach has
been validated and shown to be a significant
advantage in the long-term outcome, even
though ATO therapy has not yet been
identified as the optimal therapy for relapsed
patients [28, 29]. Two studies showed the
predictive value of the molecular detection of
relapse: Diverio et al. prospectively detected 21
positive PCRs in the entire cohort of 163
untreated patients receiving the AIDA
protocol. Of them, 20/21 experienced a further
hematological relapse with a short time interval
(3 months, range 1–14) [27]. Similarly, Jurcic
et al. demonstrated that in 7/10 cases of
molecular relapse (either after the first or
subsequent remission), a further hematological
relapse occurred [32].
These data, associated with the evidence that
most relapses occur during the first 3 years after
consolidation, led to the indication in current
guidelines that molecular monitoring should be
performed every 3 months for the first 3 years
after the end of consolidation [9, 11, 13–52].
With the increased sensitivity of last generation
RQ-PCR tools, concerns about the possibility of
monitoring MRD by PB were posed: although
some studies proposed interesting experiences
with MRD monitoring with PB, lack of
validation impaired the real clinical utility of
this approach. In particular, a comparative
analysis between PB and BM evaluation
showed the superiority of BM with an average
1.5 log sensitivity [34, 40].
The optimal treatment of relapsed APL was
progressively refined together with the
improvement of first-line therapy: in the AIDA
and PETHEMA studies [19, 20], treatment
strategies at molecular relapse were different
(autologous stem cell transplantation, further
chemotherapy schedules) and case tailored, and
different authors have approached this
problem. In the pre-ATO era, salvage therapy
with ATRA conferred only a partial advantage in
the outcome of patients: Lo-Coco et al. reported
that early intervention when molecular relapse
occurred with ATRA was efficacious (2-year OS
of 92%), but suboptimal results were obtained
when the same regimens were administered in
overt hematological relapse (44%) [28].
The introduction of ATO as a specific therapy
for relapsed APL improved the clinical outcome
of relapsed patients: preliminary evidence of
ATO efficacy was provided by Chinese groups in
the 1990s [53]. In 1999 Niu et al. demonstrated
the efficacy of ATO in APL patients (11 newly
diagnosed and 47 relapsed patients).
Surprisingly, ATO guaranteed 85.1% ORR, but
with a 2-year DFS of 41.6%. Furthermore, a
molecular assessment was performed with
RT-PCR, but the high percentage of molecular
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positivity (14/15) probably was largely sustained
by the premature evaluation performed
immediately after the achievement of the
hematological response [54].
These results were subsequently confirmed
by other experiences [55–57], and,
consequently, ATO was approved as the
standard therapy for relapsed APL [13], with
reported CR rates ranging between 80–90%.
Regarding the molecular clearance of
PML-RARa with ATO, recently Shen et al. [58]
evaluated the clearance of PML-RARa in
patients with APL with RQ-PCR: 61 patients
were randomized to receive ATRA, ATO or their
combination. Although CR was similar in the
three groups (C90%), the median time to
achieve morphologic and molecular CR was
significantly shorter in the combination arm,
and this difference also lasted after
consolidation. In particular, clearance of
PML-RARa was higher with ATO monotherapy
compared to ATRA, but only few data were
available in the literature.
The optimal consolidation therapy after
ATO-induced second remission is still a
controversial point, and this is largely due to
the restricted number of patients with resistant
disease. Interesting data were reported by
Lo-Coco et al. with gemtuzumab ozogamycin
in the second or more advanced molecular
relapse or in patients in first molecular relapse
not eligible for conventional therapies. MRD
evaluation was assessed after two doses at 6 mg/
m2; all patients achieved a molecular CR after
the third dose with a median duration of
molecular response of 15 months [59].
The best transplant procedure in relapsed/
refractory APL was not identified: autologous
HSCT guarantees a better safety profile but is
free from any graft versus leukemia effect;
furthermore, the hypothetical risk of stem cell
harvest contamination may impair the use of
this procedure [13]. For this reason, MRD
evaluation before the stem cell harvest is a
critical point and should guide the following
therapeutic strategies. Meloni et al.
demonstrated the need for an MRD evaluation
on stem cell harvesting before autologous
HSCT, because all patients who underwent
this procedure with positive MRD relapsed,
while none of the negative patients showed
the same behavior [60].
According to the current guidelines, it seems
reasonable that the choice of the allogeneic HSCT
should be reserved for patients who failed to
achieve a second CR or for patients with a short
first molecular remission [52, 61]. The MRD
monitoring also has a place during follow-up in
patients who have undergone allogeneic
transplantation, and it is interesting that in a
paper by Lo-Coco et al. [62] the subsequent
negativity of MRD was obtained without the use
of ATRA or ATO, but only with the enhancement
of the graft versus leukemia effect obtained by
reducing immunosuppressive therapy.
CONCLUSION
Unlike other acute myeloid leukemias,
biological and clinical improvements in the
APL understanding have revolutionized the
outcome of a traditionally fatal disease. The
homogeneity of the molecular hallmark in APL
patients allowed confirming the diagnosis of
APL and further introducing the possibility of
preemptive therapy that has demonstrated its
validity in reducing mortality. The assessment
of molecular remission in BM is now the
standard of care in APL treatment, considering
the evidence cited above, although the effect on
the mortality and morbidity of sequential
monitoring has not been evaluated in a
randomized trial. Some authors have raised
the question whether standard MRD
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monitoring for low-risk patients has
significance after the post-consolidation time
point, considering the low risk of relapse and
costs related to molecular monitoring after this
time point [63]. Some considerations should be
made regarding this critical point: it has to be
considered that also some low-risk patients can
have a slow clearance of the molecular burden
and as in high-risk patients an early
discontinuation of molecular monitoring can
induce a higher rate of relapses. Moreover, all
these considerations born from the results
obtained with standard therapy, including
antracyclines and ATRA, also have to be
considered; the introduction of a novel
treatment strategy with the association of
ATRA and ATO could induce a different
clearance of the molecular burden;
subsequently, the time for MRD assessment
could be completely different from what has
been demonstrated. Burnett et al. recently
published an MRD evaluation in ATRA plus
ATO as frontline therapy: the results
demonstrated that all patients (including
high-risk patients) treated with ATRA plus
ATO who achieved a molecular remission did
not experience a further relapse of disease. If
these data are confirmed by other experiences,
it may redefine the role of MRD monitoring in
this setting of patients [64].
Although the role of MRD monitoring is well
established, it is limited in particular settings:
about 10% of morphologic-resembling APL
presented an aberrant rearrangement pattern
involving other responsible genes, in some cases
(PLZF-RARa and STAT5b- RARa) with a
well-known insensitivity to retinoids [65].
Currently, there are virtually no data on
molecular monitoring in PLZF-RARa and
STAT5b-RARa-positive diseases, which have
been associated with a poor prognosis,
although Jovanovic et al. reported the
possibility of MRD monitoring in this subset
of patients and designed a specific RQ-PCR for
MRD evaluation, with interesting results [66]. In
conclusion, MRD monitoring remains an
important tool in APL management;
cooperative randomization trials could provide
more information regarding the optimal MRD
management, considering the advent of novel
and less toxic therapeutic strategies.
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